LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe

By LabMedica International staff writers
Posted on 01 May 2024
Print article
Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)
Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)

Thermo Fisher Scientific (Waltham, MA USA) has entered into a strategic distribution agreement with Bio-Techne Corporation (Minneapolis, MN, USA), resulting in a significant collaboration between two industry leaders in scientific research, diagnostics, and biotechnology. As per the agreement, Thermo Fisher will distribute Bio-Techne's wide range of products, including antibodies, proteins, immunoassay kits, reagents, and enzymes to laboratories and research institutions across Europe through the European arm of its Fisher Scientific Channel.

Bio-Techne's products are designed to speed up research and enhance outcomes in areas such as cell and gene therapy, immunology, neuroscience, and others. Following this collaboration, Thermo Fisher has reinforced its commitment to providing access to its clients with the most advanced technologies and expertise, eventually resulting in advancements in scientific knowledge and improvement in human health. The distribution agreement highlights Thermo Fisher's dedication to encouraging innovation and collaboration among members of the scientific community. By entering into strategic partnerships with leading companies such as Bio-Techne, Thermo Fisher maintains its position as a trusted partner for researchers and laboratories across Europe.

"We are thrilled to forge this partnership with Bio-Techne, a company renowned for its pioneering advancements in the life sciences industry," said Claire Wallace, President Research and Safety Market, Europe at Thermo Fisher. "By adding Bio-Techne's high-quality products to our comprehensive portfolio, we aim to further empower scientists and researchers with the tools they need to drive breakthrough discoveries and advancements in healthcare."

"We are excited to partner with Thermo Fisher to expand the reach of our products and services throughout Europe," said Kim Kelderman, Bio-Techne's President and Chief Executive Officer. "By leveraging the Fisher Scientific Channel's extensive European distribution network and industry expertise, we aim to enhance support for researchers and accelerate scientific discoveries that address some of the most pressing challenges in healthcare today."

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.